PD-1/PD-L1治疗非小细胞肺癌的研究进展

阎卫亮; 王华庆

doi:10.3969/j.issn.1000-8179.2018.13.399

PD-1/PD-L1治疗非小细胞肺癌的研究进展

doi: 10.3969/j.issn.1000-8179.2018.13.399

阎卫亮^①,,
王华庆^②, ,

①.
天津医科大学第二医院胸外科（天津市300211）
②.
天津市人民医院

详细信息

作者简介:
阎卫亮专业方向为胸部肿瘤基础与临床研究。E-mail：yanweiliangy@sina.com

通讯作者:
王华庆 hxd_204@163.com

计量
- 文章访问数: 59
- HTML全文浏览量: 8
- PDF下载量: 8
- 被引次数: 0
出版历程
- 收稿日期: 2018-04-16
- 修回日期: 2018-06-18
- 刊出日期: 2018-07-15

Research progress of PD-1/PD-L1 in the treatment of non-small cell lung cancer

Yan Weiliang^{①
,},
Wang Huaqing^{②
, ,}

①.
Department of Thoracic Surgery, The Second Hospital of Tianjin Medical University, Tianjin 200211, China
②.
Tianjin People's Hospital, 300000, China

More Information

Corresponding author: Huaqing Wang; hxd_204@163.com

摘要

摘要: 程序性死亡受体-1（programmed cell death-1，PD-1）/程序性死亡配体-1（programmed cell death-ligand 1，PD-L1）信号通路与肿瘤免疫逃逸密切相关，针对PD-1/PD-L1通路的免疫检查点抑制剂为非小细胞肺癌（non-small cell lung cancer，NSCLC）患者提供了一种新的治疗选择，并且显示出良好的疗效和安全性。本文对PD-1/PD-L1抑制剂治疗NSCLC的临床研究进展进行综述。
- 免疫治疗 /
- 程序性死亡受体-1 /
- 程序性死亡配体-1 /
- 非小细胞肺癌
Abstract: The programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) signaling pathway is closely related to the immune escape mechanism. Immune checkpoint inhibitors targeting PD-1/PD-L1 have become an important alternative for treating advanced non-small cell lung cancer (NSCLC) patients; NSCLC patients have shown considerable responses and good tolerance to these agents. The article reviews the current clinical researches on PD-1/PD-L1 for NSCLC treatment.
- immunity therapy /
- programmed cell death-1 /
- programmed cell death-ligand 1 /
- non-small cell lung cancer

HTML全文

参考文献(35)

[1]	Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2):69-90. doi: 10.3322/caac.v61:2
[2]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015[J]. CA Cancer J Clin, 2015, 65(1):5-29. doi: 10.3322/caac.21254
[3]	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132. doi: 10.3322/caac.21338
[4]	Aisner DL, Marshall CB. Molecular pathology of non-small cell lung cancer: a practical guide[J]. Am J Clin Pathol, 2012, 138(3):332-346. doi: 10.1309/AJCPFR12WJKCEEZZ
[5]	Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J]. N Engl J Med, 2002, 346(2):92-98. doi: 10.1056/NEJMoa011954
[6]	Kelly K, Crowley J, Bunn PA, et al. Randomized phase Ⅲ trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a southwest oncology group trial[J]. J Clin Oncol, 2001, 19(13):3210-3218. doi: 10.1200/JCO.2001.19.13.3210
[7]	Sher DJ, Koshy M, Liptay MJ, et al. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage Ⅲ non-small cell lung cancer in the national cancer data base[J]. Cancer, 2014, 120(13):2060-2068. doi: 10.1002/cncr.28677
[8]	Ettinger DS, Akerley W, Borghaei H, et al. Non-small cell lung cancer, version 2.2013[J]. J Nati Compr Cancer Netw, 2013, 11(6):645-653. doi: 10.6004/jnccn.2013.0084
[9]	Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited[J]. Ann Rev Immunol, 2005, (23):515-548. http://cn.bing.com/academic/profile?id=ed96f98dd620984834095c7d3bc65685&encoded=0&v=paper_preview&mkt=zh-cn
[10]	Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death[J]. EMBO J, 1992, 11(11):3887-3895. http://cn.bing.com/academic/profile?id=34a10c19a17f223f27b72eb11c68f430&encoded=0&v=paper_preview&mkt=zh-cn
[11]	Carreno BM, Collins M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses[J]. Ann Rev Immunol, 2002, (20):29-53. http://cn.bing.com/academic/profile?id=11cd22201b09a7f9c23981dbd4e4e439&encoded=0&v=paper_preview&mkt=zh-cn
[12]	Konishi J, Yamazaki K, Azuma M, et al. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression[J]. Clin Cancer Res, 2004, 10 (15):5094-5100. doi: 10.1158/1078-0432.CCR-04-0428
[13]	Aerts JG, Hegmans JP. Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer [J]. Cancer Res, 2013, 73(8):2381-2388. doi: 10.1158/0008-5472.CAN-12-3932
[14]	Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J]. N Engl J Med, 2012, 366 (26):2443-2454. doi: 10.1056/NEJMoa1200690
[15]	Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-smallcell lung cancer[J]. J Clin Oncol, 2015, 33(18):2004-2012. doi: 10.1200/JCO.2014.58.3708
[16]	Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phaseⅡ, single-arm trial[J]. Lancet Oncol, 2015, 16(3): 257-265. doi: 10.1016/S1470-2045(15)70054-9
[17]	Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(2):123-135. doi: 10.1056/NEJMoa1504627
[18]	Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer[J]. Engl J Med, 2015, 373(17):1627-1639. doi: 10.1056/NEJMoa1507643
[19]	Gettinger S, Rizvi NA, Chow LQ, et al. Nivolumab monotherapy for firstline treatment of advanced non-small-cell lung cancer[J]. J Clin Oncol, 2016, 34(25):2980-2987. doi: 10.1200/JCO.2016.66.9929
[20]	Carbone DP, Reck M, Paz-Ares L, et al. First-line nivolumab in stage Ⅳ or recurrent non-small-cell lung cancer[J]. NEngl J Med, 2017, 376(25): 2415-2426. doi: 10.1056/NEJMoa1613493
[21]	Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phaseⅠ, multicohort study [J]. Lancet Oncol, 2017, 18(1):31-41. doi: 10.1016/S1470-2045(16)30624-6
[22]	Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer[J]. Lancet Oncol, 2015, 372(21):2018-2028. http://cn.bing.com/academic/profile?id=b5fdf921a36a022f81ffe36a1ac40261&encoded=0&v=paper_preview&mkt=zh-cn
[23]	Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial[J]. Lancet, 2016, 387(10027):1540-1550. doi: 10.1016/S0140-6736(15)01281-7
[24]	Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous nonsmall-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study[J]. Lancet Oncol, 2016, 17(11):1497-1508. doi: 10.1016/S1470-2045(16)30498-3
[25]	Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous nonsmall-cell lung cancer: a randomised, phase Ⅱ cohort of the openlabel KEYNOTE-021 study[J]. N Engl J Med, 2016, 17(11):1497-1508.
[26]	Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients[J]. N Engl J Med, 2014, 515(7528):563-567. http://cn.bing.com/academic/profile?id=39119c38dfd307fb15ac641e6e030297&encoded=0&v=paper_preview&mkt=zh-cn
[27]	Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase Ⅱ randomised controlled trial[J]. Lancet, 2016, 387(10030):1837-1846. doi: 10.1016/S0140-6736(16)00587-0
[28]	Besse B, Johnson M, Jänne PA, et al. PhaseⅡ, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advancedormetastaticPD-L1-selectednon-small cell lungcancer(NSCLC) [J]. J Clin Oncol, 2015, (51):S717-S718.
[29]	Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase Ⅲ, open-label, multicentre randomised controlled trial[J]. Lancet, 2017, 389(10066):255-265. doi: 10.1016/S0140-6736(16)32517-X
[30]	Rizvi N, Brahmer J, Ou SH, et al. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol, 2015, 33(15 suppl):8032.
[31]	Antonia S, Goldberg SB, Balmanoukian A, et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase Ⅰb study[J]. Lancet Oncol, 2016, 17(3): 299-308. doi: 10.1016/S1470-2045(15)00544-6
[32]	Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-smallcell lung cancer[J]. J Clin Oncol, 2010, 28(13):2181-2190. doi: 10.1200/JCO.2009.26.2543
[33]	Tomasini P, Greillier L, Boyer A, et al. Durvalumab after chemoradiotherapy in stage Ⅲ non-small cell lung cancer[J]. Thorac Dis, 2018, 10 (Suppl 9):S1032-S1036. http://cn.bing.com/academic/profile?id=d2180e5ba935561f748fe7e7fcc964e8&encoded=0&v=paper_preview&mkt=zh-cn
[34]	Gulley JL, Spigel D, Kelly K, et al. Avelumab (MSB-0010718C), an antiPD-L1 antibody, in advanced NSCLC patients: a phase Ⅰb, open-label expansion trial in patients progressing after platinum-based chemotherapy[J]. J Clin Oncol, 2015, 33(15 Suppl):8034.
[35]	Verschraegen CF, Chen F, Spigel DR, et al. Avelumab(MSB0010718C; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN Solid Tumor phase Ⅰb trial: Safety, clinical activity, and PD-L1 expression[J]. J Clin Oncol, 2016, 34(23):2413-2420.